FindTrial
Sign In

Lianhua Qingwen granules/capsules in the treatment of asymptomatic and mild COVID-19 in children: a single-center, retrospective cohort study

Lianhua Qingwen granules/capsules in the treatment of asymptomatic and mild COVID-19 in children: a single-center, retrospective cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200063399
Enrollment
Unknown
Registered
2022-09-06
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

exposure group:Basic treatment+Lianhua Qingwen
non-exposed group:Basic treatment

Sponsors

Jiujiang Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 17 Years

Inclusion criteria

Inclusion criteria: 1. Asymptomatic infections and mild confirmed cases of the new coronavirus by etiological testing; 2. aged 1 to 17 years old.

Exclusion criteria

Exclusion criteria: 1. Patients with serious medical conditions involving vital internal organs (heart, lung, brain, liver, and kidney) and severe hematopoietic, immunological, endocrinological, metabolic, and mental diseases; 2. Allergy to the ingredients of Lianhua Qingwen; 3. Patients with incomplete medical records.

Design outcomes

Primary

MeasureTime frame
negative time of nucleic acid test;—

Secondary

MeasureTime frame
Nucleic acid cycle threshold value;negative rate of nucleic acid test;length of hospital stay;—

Countries

China

Contacts

Public ContactHongze Wu

Jiujiang Traditional Chinese Medicine Hospital

whzzyy@163.com+86 18970256865

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026